- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01824875
Temozolomid med eller uten capecitabin ved behandling av pasienter med avanserte nevroendokrine svulster i bukspyttkjertelen
En randomisert fase II-studie av temozolomid eller temozolomid og capecitabin hos pasienter med avanserte pankreas-nevroendokrine svulster
This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. To evaluate progression-free survival (PFS) associated with temozolomide alone or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors.
SECONDARY OBJECTIVES:
I. To evaluate response rates (RR) associated with temozolomide alone or temozolomide and capecitabine treatment in patients with advanced pancreatic neuroendocrine tumors.
II. To evaluate overall survival (OS) associated with temozolomide alone or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors.
III. To evaluate the toxicity associated with temozolomide alone or temozolomide and capecitabine treatment in patients with advanced pancreatic neuroendocrine tumors.
IV. To evaluate the usefulness of methyl guanine methyltransferase (MGMT) status (by immunohistochemistry [IHC] and promoter methylation) for predicting response in pancreatic neuroendocrine tumor patients treated with either temozolomide or temozolomide and capecitabine.
V. To bank radiology images for evaluation of quality, reproducibility, and compliance with computed tomography (CT) methodology.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive temozolomide orally (PO) once daily (QD) on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive capecitabine PO twice daily (BID) on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years, and then every 6 months for 3 years.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
California
-
Anaheim, California, Forente stater, 92807
- Kaiser Anaheim Medical Center
-
Antioch, California, Forente stater, 94531
- Kaiser Permanente-Deer Valley Medical Center
-
Baldwin Park, California, Forente stater, 91706
- Kaiser Permanente Medical Group - Baldwin Park
-
Bellflower, California, Forente stater, 90706
- Kaiser Foundation Hospital
-
Berkeley, California, Forente stater, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Burlingame, California, Forente stater, 94010
- Mills - Peninsula Hospitals
-
Fontana, California, Forente stater, 92335
- Kaiser Permanente Hospital
-
Fremont, California, Forente stater, 94538
- Kaiser Permanente, Fremont
-
Fresno, California, Forente stater, 93720
- Kaiser Permanente
-
Harbor City, California, Forente stater, 90710
- Kaiser Permanente - Harbor City
-
Hayward, California, Forente stater, 94545
- Kaiser Permanente, Hayward
-
Irvine, California, Forente stater, 92618
- Southern California Permanente Medical Group
-
Los Angeles, California, Forente stater, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Forente stater, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Forente stater, 90033
- University of Southern California/Norris Cancer Center
-
Los Angeles, California, Forente stater, 90034
- Kaiser Permanente-West Los Angeles
-
Modesto, California, Forente stater, 95356
- Kaiser Permanente-Modesto
-
Novato, California, Forente stater, 94945
- Sutter Cancer Research Consortium
-
Oakland, California, Forente stater, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Forente stater, 92868
- University of California Medical Center At Irvine-Orange Campus
-
Panorama City, California, Forente stater, 91402
- Kaiser Permanente - Panorama City
-
Redwood City, California, Forente stater, 94063
- Kaiser Permanente-Redwood City
-
Richmond, California, Forente stater, 94801
- Kaiser Permanente-Richmond
-
Riverside, California, Forente stater, 92505
- Kaiser Permanente Medical Center
-
Roseville, California, Forente stater, 95661
- Kaiser Permanente-Roseville
-
Sacramento, California, Forente stater, 95823
- Kaiser Permanente-South Sacramento
-
Sacramento, California, Forente stater, 95825
- Kaiser Permanente - Sacramento
-
San Diego, California, Forente stater, 92120
- Kaiser Permanente at San Diego
-
San Diego, California, Forente stater, 92120
- Kaiser Permanente
-
San Francisco, California, Forente stater, 94115
- Kaiser Permanente-San Francisco
-
San Francisco, California, Forente stater, 94118
- California Pacific Medical Center
-
San Francisco, California, Forente stater, 94115
- UCSF-Mount Zion
-
San Jose, California, Forente stater, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Marcos, California, Forente stater, 92069
- Kaiser Permanente Health Care
-
San Rafael, California, Forente stater, 94903
- Kaiser Permanente-San Rafael
-
Santa Clara, California, Forente stater, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa, California, Forente stater, 95403
- Kaiser Permanente-Santa Rosa
-
Santa Rosa, California, Forente stater, 95403
- Sutter Pacific Medical Foundation
-
South San Francisco, California, Forente stater, 94080
- Kaiser Permanente-South San Francisco
-
Stanford, California, Forente stater, 94305
- Stanford University Hospitals and Clinics
-
Stockton, California, Forente stater, 95210
- Kaiser Permanente-Stockton
-
Vacaville, California, Forente stater, 95688
- Kaiser Permanente Medical Center-Vacaville
-
Vallejo, California, Forente stater, 94589
- Kaiser Permanente-Vallejo
-
Vallejo, California, Forente stater, 94589
- Sutter Solano Medical Center
-
Walnut Creek, California, Forente stater, 94596
- Kaiser Permanente-Walnut Creek
-
Woodland Hills, California, Forente stater, 91367
- Kaiser Permanente
-
-
Connecticut
-
Hartford, Connecticut, Forente stater, 06105
- Saint Francis Hospital and Medical Center
-
Middletown, Connecticut, Forente stater, 06457
- Middlesex Hospital
-
-
Delaware
-
Lewes, Delaware, Forente stater, 19958
- Beebe Medical Center
-
Newark, Delaware, Forente stater, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Forente stater, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Forente stater, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Forente stater, 19718
- Christiana Care Health System-Christiana Hospital
-
Newark, Delaware, Forente stater, 19713
- Christiana Gynecologic Oncology LLC
-
Newark, Delaware, Forente stater, 19713
- Regional Hematology and Oncology PA
-
Rehoboth Beach, Delaware, Forente stater, 19971
- Beebe Health Campus
-
Seaford, Delaware, Forente stater, 19973
- Nanticoke Memorial Hospital
-
Wilmington, Delaware, Forente stater, 19801
- Christiana Care Health System-Wilmington Hospital
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32207
- Edna Williams Cancer Center at the Baptist Cancer Institute
-
Miami, Florida, Forente stater, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orlando, Florida, Forente stater, 32803
- Florida Hospital
-
Tampa, Florida, Forente stater, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Forente stater, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Forente stater, 96819
- Kaiser Permanente Moanalua Medical Center
-
Honolulu, Hawaii, Forente stater, 96813
- University of Hawaii
-
Honolulu, Hawaii, Forente stater, 96813
- Oncare Hawaii Inc-POB II
-
Honolulu, Hawaii, Forente stater, 96817-3169
- OnCare Hawaii-Liliha
-
Honolulu, Hawaii, Forente stater, 96817
- Oncare Hawaii Inc-Kuakini
-
Kailua, Hawaii, Forente stater, 96734
- Castle Medical Center
-
Lihue, Hawaii, Forente stater, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Forente stater, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Forente stater, 96701
- Oncare Hawaii Inc-Pali Momi
-
-
Idaho
-
Boise, Idaho, Forente stater, 83706
- Saint Alphonsus Regional Medical Center
-
-
Illinois
-
Bloomington, Illinois, Forente stater, 61701
- Saint Joseph Medical Center
-
Bloomington, Illinois, Forente stater, 61701
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Forente stater, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Forente stater, 62902
- Memorial Hospital of Carbondale
-
Carthage, Illinois, Forente stater, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Forente stater, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University
-
Chicago, Illinois, Forente stater, 60612
- University of Illinois
-
Decatur, Illinois, Forente stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forente stater, 62526
- Cancer Care Center of Decatur
-
Effingham, Illinois, Forente stater, 62401
- Crossroads Cancer Center
-
Eureka, Illinois, Forente stater, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Forente stater, 61401
- Illinois CancerCare Galesburg
-
Galesburg, Illinois, Forente stater, 61401
- Illinois CancerCare-Galesburg Cottage Plaza Office
-
Highland Park, Illinois, Forente stater, 60035
- Hematology Oncology Associates of Illinois-Highland Park
-
Hinsdale, Illinois, Forente stater, 60521
- Hinsdale Hematology Oncology Associates Incorporated
-
Kankakee, Illinois, Forente stater, 60901
- Presence Saint Mary's Hospital
-
Kewanee, Illinois, Forente stater, 61443
- Illinois CancerCare-Kewanee Clinic
-
Libertyville, Illinois, Forente stater, 60048
- North Shore Hematology Oncology
-
Macomb, Illinois, Forente stater, 61455
- Illinois CancerCare-Macomb
-
Maywood, Illinois, Forente stater, 60153
- Loyola University Medical Center
-
Moline, Illinois, Forente stater, 61265
- Garneau, Stewart C MD (UIA Investigator)
-
Moline, Illinois, Forente stater, 61265
- Porubcin, Michael MD (UIA Investigator)
-
Moline, Illinois, Forente stater, 61265
- Spector, David MD (UIA Investigator)
-
Moline, Illinois, Forente stater, 61265
- Trinity Medical Center
-
Monmouth, Illinois, Forente stater, 61462
- Illinois CancerCare-Monmouth
-
Mount Vernon, Illinois, Forente stater, 62864
- Good Samaritan Regional Health Center
-
Niles, Illinois, Forente stater, 60714
- Illinois Cancer Specialists-Niles
-
Normal, Illinois, Forente stater, 61761
- Community Cancer Center Foundation
-
Ottawa, Illinois, Forente stater, 61350
- Illinois CancerCare-Ottawa Clinic
-
Ottawa, Illinois, Forente stater, 61350
- Ottawa Regional Hospital and Healthcare Center
-
Pekin, Illinois, Forente stater, 61554
- Pekin Cancer Treatment Center
-
Pekin, Illinois, Forente stater, 61603
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forente stater, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Forente stater, 61615
- Illinois CancerCare-Peoria
-
Peoria, Illinois, Forente stater, 61614
- Proctor Hospital
-
Peoria, Illinois, Forente stater, 61603
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Forente stater, 61615
- Illinois Oncology Research Association CCOP
-
Peru, Illinois, Forente stater, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Forente stater, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Forente stater, 61107
- SwedishAmerican Regional Cancer Center/ACT
-
Skokie, Illinois, Forente stater, 60076
- Hematology Oncology Associates of Illinois - Skokie
-
Springfield, Illinois, Forente stater, 62781-0001
- Memorial Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46237
- Franciscan Saint Francis Health-Indianapolis
-
Richmond, Indiana, Forente stater, 47374
- Reid Hospital and Health Care Services
-
-
Iowa
-
Ames, Iowa, Forente stater, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Forente stater, 50010
- McFarland Clinic PC-William R Bliss Cancer Center
-
Bettendorf, Iowa, Forente stater, 52722
- Constantinou, Costas L MD (UIA Investigator)
-
Boone, Iowa, Forente stater, 50036
- McFarland Clinic PC-Boone
-
Clive, Iowa, Forente stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forente stater, 50325
- Medical Oncology and Hematology Associates-West Des Moines
-
Des Moines, Iowa, Forente stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forente stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forente stater, 50309
- Medical Oncology and Hematology Associates-Des Moines
-
Des Moines, Iowa, Forente stater, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Forente stater, 50314
- Medical Oncology and Hematology Associates-Laurel
-
Des Moines, Iowa, Forente stater, 50309
- Iowa Oncology Research Association CCOP
-
Jefferson, Iowa, Forente stater, 50129
- McFarland Clinic PC-Jefferson
-
Marshalltown, Iowa, Forente stater, 50158
- McFarland Clinic PC-Marshalltown
-
Sioux City, Iowa, Forente stater, 51104
- Saint Luke's Regional Medical Center
-
Sioux City, Iowa, Forente stater, 51101
- Siouxland Hematology Oncology Associates
-
Sioux City, Iowa, Forente stater, 51104
- Mercy Medical Center-Sioux City
-
West Des Moines, Iowa, Forente stater, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, Forente stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Chanute, Kansas, Forente stater, 66720
- Cancer Center of Kansas - Chanute
-
Dodge City, Kansas, Forente stater, 67801
- Cancer Center of Kansas - Dodge City
-
El Dorado, Kansas, Forente stater, 67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott, Kansas, Forente stater, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Forente stater, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, Forente stater, 67068
- Cancer Center of Kansas-Kingman
-
Lawrence, Kansas, Forente stater, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Forente stater, 67901
- Cancer Center of Kansas-Liberal
-
Manhattan, Kansas, Forente stater, 66502
- Cancer Center of Kansas-Manhattan
-
McPherson, Kansas, Forente stater, 67460
- Cancer Center of Kansas - McPherson
-
Newton, Kansas, Forente stater, 67114
- Cancer Center of Kansas - Newton
-
Parsons, Kansas, Forente stater, 67357
- Cancer Center of Kansas - Parsons
-
Pratt, Kansas, Forente stater, 67124
- Cancer Center of Kansas - Pratt
-
Salina, Kansas, Forente stater, 67401
- Cancer Center of Kansas - Salina
-
Wellington, Kansas, Forente stater, 67152
- Cancer Center of Kansas - Wellington
-
Wichita, Kansas, Forente stater, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Forente stater, 67208
- Associates In Womens Health
-
Wichita, Kansas, Forente stater, 67214
- Cancer Center of Kansas - Main Office
-
Wichita, Kansas, Forente stater, 67214
- Via Christi Regional Medical Center
-
Wichita, Kansas, Forente stater, 67214
- Wichita CCOP
-
Winfield, Kansas, Forente stater, 67156
- Cancer Center of Kansas - Winfield
-
-
Kentucky
-
Crestview Hills, Kentucky, Forente stater, 41017
- Oncology Hematology Care Incorporated
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70809
- Ochsner Health Center-Summa
-
New Orleans, Louisiana, Forente stater, 70121
- Ochsner Medical Center Jefferson
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02118
- Boston Medical Center
-
Burlington, Massachusetts, Forente stater, 01805
- Lahey Hospital and Medical Center
-
-
Michigan
-
Adrian, Michigan, Forente stater, 49221
- Bixby Medical Center
-
Adrian, Michigan, Forente stater, 49221
- Hickman Cancer Center
-
Ann Arbor, Michigan, Forente stater, 48106-0995
- Saint Joseph Mercy Hospital
-
Ann Arbor, Michigan, Forente stater, 48106
- Michigan Cancer Research Consortium Community Clinical Oncology Program
-
Ann Arbor, Michigan, Forente stater, 48109
- University of Michigan University Hospital
-
Dearborn, Michigan, Forente stater, 48124
- Oakwood Hospital
-
Detroit, Michigan, Forente stater, 48236
- Saint John Hospital and Medical Center
-
Flint, Michigan, Forente stater, 48502
- Hurley Medical Center
-
Flint, Michigan, Forente stater, 48503
- Genesys Hurley Cancer Institute
-
Jackson, Michigan, Forente stater, 49201
- Allegiance Health
-
Kalamazoo, Michigan, Forente stater, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Forente stater, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Forente stater, 49001
- Borgess Medical Center
-
Lansing, Michigan, Forente stater, 48912
- Sparrow Hospital
-
Livonia, Michigan, Forente stater, 48154
- Saint Mary Mercy Hospital
-
Monroe, Michigan, Forente stater, 48162
- Mercy Memorial Hospital
-
Monroe, Michigan, Forente stater, 48162
- Community Cancer Center of Monroe
-
Pontiac, Michigan, Forente stater, 48341-2985
- Saint Joseph Mercy Oakland
-
Port Huron, Michigan, Forente stater, 48060
- Saint Joseph Mercy Port Huron
-
Saginaw, Michigan, Forente stater, 48601
- Saint Mary's of Michigan
-
Warren, Michigan, Forente stater, 48093
- Saint John Macomb-Oakland Hospital
-
-
Minnesota
-
Burnsville, Minnesota, Forente stater, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Forente stater, 55433
- Mercy Hospital
-
Edina, Minnesota, Forente stater, 55435
- Fairview-Southdale Hospital
-
Fridley, Minnesota, Forente stater, 55432
- Unity Hospital
-
Hutchinson, Minnesota, Forente stater, 55350
- Hutchinson Area Health Care
-
Maplewood, Minnesota, Forente stater, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Forente stater, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Forente stater, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Forente stater, 55407
- Abbott-Northwestern Hospital
-
New Ulm, Minnesota, Forente stater, 56073
- New Ulm Medical Center
-
Robbinsdale, Minnesota, Forente stater, 55422
- North Memorial Medical Health Center
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Metro-Minnesota CCOP
-
Saint Paul, Minnesota, Forente stater, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Forente stater, 55102
- United Hospital
-
Shakopee, Minnesota, Forente stater, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Forente stater, 55082
- Lakeview Hospital
-
Waconia, Minnesota, Forente stater, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Forente stater, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Forente stater, 55125
- Minnesota Oncology and Hematology PA-Woodbury
-
-
Missouri
-
Bolivar, Missouri, Forente stater, 65613
- Central Care Cancer Center-Carrie J Babb Cancer Center
-
Branson, Missouri, Forente stater, 65616
- CoxHealth Cancer Center
-
Cape Girardeau, Missouri, Forente stater, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Forente stater, 63703
- Southeast Cancer Center
-
Jefferson City, Missouri, Forente stater, 65109
- Capital Region Medical Center-Goldschmidt Cancer Center
-
Rolla, Missouri, Forente stater, 65401
- Phelps County Regional Medical Center
-
Rolla, Missouri, Forente stater, 65401
- Saint John's Clinic-Rolla-Cancer and Hematology
-
Springfield, Missouri, Forente stater, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Forente stater, 65804
- Mercy Hospital Springfield
-
Springfield, Missouri, Forente stater, 65802
- Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield
-
St Louis, Missouri, Forente stater, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Forente stater, 63109
- Saint Louis Cancer and Breast Institute-South City
-
St Louis, Missouri, Forente stater, 63141
- Saint John's Mercy Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89106
- Nevada Cancer Research Foundation CCOP
-
-
New Jersey
-
Camden, New Jersey, Forente stater, 08103
- Cooper Hospital University Medical Center
-
Mount Holly, New Jersey, Forente stater, 08060
- Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County
-
Voorhees Township, New Jersey, Forente stater, 08043
- Virtua West Jersey Hospital Voorhees
-
-
New York
-
Albany, New York, Forente stater, 12208
- New York Oncology Hematology PC -Albany Medical Center
-
Albany, New York, Forente stater, 12206
- New York Oncology Hematology PC - Albany
-
Amsterdam, New York, Forente stater, 12010
- New York Oncology Hematology PC - Amsterdam
-
Hudson, New York, Forente stater, 12534
- New York Oncology Hematology PC-Hudson
-
Latham, New York, Forente stater, 12110
- New York Oncology Hematology PC - Latham
-
Rexford, New York, Forente stater, 12148
- New York Oncology Hematology PC - Rexford
-
Rochester, New York, Forente stater, 14642
- University of Rochester
-
The Bronx, New York, Forente stater, 10467-2490
- Montefiore Medical Center
-
The Bronx, New York, Forente stater, 10461
- Montefiore Medical Center-Weiler Division
-
Troy, New York, Forente stater, 12180
- New York Oncology Hematology PC - Troy
-
-
North Carolina
-
Kinston, North Carolina, Forente stater, 28501
- Kinston Medical Specialists PA
-
Statesville, North Carolina, Forente stater, 28677
- Iredell Memorial Hospital
-
-
Ohio
-
Akron, Ohio, Forente stater, 44307
- Akron General Medical Center
-
Beachwood, Ohio, Forente stater, 44122
- Cleveland Clinic Cancer Center Beachwood
-
Belpre, Ohio, Forente stater, 45714
- Strecker Cancer Center-Belpre
-
Bowling Green, Ohio, Forente stater, 43402
- Toledo Clinic Cancer Centers-Bowling Green
-
Chillicothe, Ohio, Forente stater, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, Forente stater, 45267
- University of Cincinnati
-
Cincinnati, Ohio, Forente stater, 45230
- Oncology Hematology Care Inc - Anderson
-
Cincinnati, Ohio, Forente stater, 45236
- Oncology Hematology Care Inc - Kenwood
-
Cincinnati, Ohio, Forente stater, 45219
- Oncology and Hematology Care Incorporated
-
Cincinnati, Ohio, Forente stater, 45242
- Oncology and Hematology Care Inc - Blue Ash
-
Cincinnati, Ohio, Forente stater, 45248
- Oncology Hematology Care Inc - Western Hills
-
Cleveland, Ohio, Forente stater, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Forente stater, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Forente stater, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Forente stater, 43210
- Ohio State University Medical Center
-
Columbus, Ohio, Forente stater, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Forente stater, 43228
- Doctors Hospital
-
Columbus, Ohio, Forente stater, 43215
- Grant Medical Center
-
Columbus, Ohio, Forente stater, 43222
- Mount Carmel Health Center West
-
Columbus, Ohio, Forente stater, 43215
- Columbus CCOP
-
Dayton, Ohio, Forente stater, 45406
- Good Samaritan Hospital - Dayton
-
Dayton, Ohio, Forente stater, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Forente stater, 45415
- Samaritan North Health Center
-
Dayton, Ohio, Forente stater, 45405
- Grandview Hospital
-
Dayton, Ohio, Forente stater, 45420
- Dayton CCOP
-
Delaware, Ohio, Forente stater, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Forente stater, 43015
- Delaware Radiation Oncology
-
Delaware, Ohio, Forente stater, 43015
- Grady Memorial Hospital
-
Elyria, Ohio, Forente stater, 44035
- Mercy Cancer Center-Elyria
-
Elyria, Ohio, Forente stater, 44035
- Hematology Oncology Center Incorporated
-
Fairfield, Ohio, Forente stater, 45014
- Oncology Hematology Care Inc
-
Findlay, Ohio, Forente stater, 45840
- Blanchard Valley Hospital
-
Franklin, Ohio, Forente stater, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Forente stater, 45331
- Wayne Hospital
-
Independence, Ohio, Forente stater, 44131
- Cleveland Clinic Cancer Center Independence
-
Kettering, Ohio, Forente stater, 45429
- Kettering Medical Center
-
Lancaster, Ohio, Forente stater, 43130
- Fairfield Medical Center
-
Lancaster, Ohio, Forente stater, 43130
- Lancaster Radiation Oncology
-
Lima, Ohio, Forente stater, 45801
- Saint Rita's Medical Center
-
Lima, Ohio, Forente stater, 45804
- Lima Memorial Hospital
-
Marietta, Ohio, Forente stater, 45750
- Marietta Memorial Hospital
-
Maumee, Ohio, Forente stater, 43537
- Toledo Clinic Cancer Centers-Maumee
-
Maumee, Ohio, Forente stater, 43537
- Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
-
Mayfield Heights, Ohio, Forente stater, 44124
- Hillcrest Hospital Cancer Center
-
Mount Vernon, Ohio, Forente stater, 43050
- Knox Community Hospital
-
Newark, Ohio, Forente stater, 43055
- Licking Memorial Hospital
-
Newark, Ohio, Forente stater, 43055
- Newark Radiation Oncology
-
Oregon, Ohio, Forente stater, 43616
- Saint Charles Hospital
-
Oregon, Ohio, Forente stater, 43616
- Toledo Clinic Cancer Centers-Oregon
-
Portsmouth, Ohio, Forente stater, 45662
- Southern Ohio Medical Center
-
Sandusky, Ohio, Forente stater, 44870
- North Coast Cancer Care
-
Springfield, Ohio, Forente stater, 45505
- Springfield Regional Medical Center
-
Strongsville, Ohio, Forente stater, 44136
- Cleveland Clinic Cancer Center-Strongsville
-
Sylvania, Ohio, Forente stater, 43560
- Flower Hospital
-
Tiffin, Ohio, Forente stater, 44883
- Mercy Hospital of Tiffin
-
Toledo, Ohio, Forente stater, 43608
- Saint Vincent Mercy Medical Center
-
Toledo, Ohio, Forente stater, 43623
- Toledo Clinic Cancer Centers-Toledo
-
Toledo, Ohio, Forente stater, 43614
- University of Toledo
-
Toledo, Ohio, Forente stater, 43617
- Toledo Community Hospital Oncology Program CCOP
-
Toledo, Ohio, Forente stater, 43606
- The Toledo Hospital/Toledo Children's Hospital
-
Toledo, Ohio, Forente stater, 43623
- Mercy Saint Anne Hospital
-
Troy, Ohio, Forente stater, 45373
- Upper Valley Medical Center
-
Wauseon, Ohio, Forente stater, 43567
- Fulton County Health Center
-
Westerville, Ohio, Forente stater, 43081
- Saint Ann's Hospital
-
Xenia, Ohio, Forente stater, 45385
- Greene Memorial Hospital
-
Zanesville, Ohio, Forente stater, 43701
- Genesis HealthCare System
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Forente stater, 74146
- Tulsa Cancer Institute
-
-
Pennsylvania
-
Danville, Pennsylvania, Forente stater, 17822-2001
- Geisinger Medical Center
-
Hazleton, Pennsylvania, Forente stater, 18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Hershey, Pennsylvania, Forente stater, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Lewisburg, Pennsylvania, Forente stater, 17837
- Geisinger Medical Oncology at Evangelical Community Hospital
-
Philadelphia, Pennsylvania, Forente stater, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Thomas Jefferson University Hospital
-
Pottsville, Pennsylvania, Forente stater, 17901
- Geisinger Medical Oncology-Pottsville
-
State College, Pennsylvania, Forente stater, 16801
- Geisinger Medical Group
-
West Reading, Pennsylvania, Forente stater, 19611
- Reading Hospital
-
Wilkes-Barre, Pennsylvania, Forente stater, 18711
- Geisinger Wyoming Valley
-
-
South Carolina
-
Greenville, South Carolina, Forente stater, 29605
- Greenville Health System Cancer Institute-Butternut
-
Greenville, South Carolina, Forente stater, 29615
- Greenville Health System Cancer Institute/Greenville CCOP
-
Greer, South Carolina, Forente stater, 29650
- Greenville Health System Cancer Institute-Greer
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232-6838
- Vanderbilt Cancer Center
-
-
Virginia
-
Fredericksburg, Virginia, Forente stater, 22401
- Fredericksburg Oncology Inc
-
-
Wisconsin
-
La Crosse, Wisconsin, Forente stater, 54601
- Gundersen Lutheran
-
Madison, Wisconsin, Forente stater, 53792
- University of Wisconsin Hospital and Clinics
-
Milwaukee, Wisconsin, Forente stater, 53226
- Froedtert and the Medical College of Wisconsin
-
New Richmond, Wisconsin, Forente stater, 54017
- Cancer Center of Western Wisconsin
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patient must have histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor
-
Patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained <= 4 weeks prior to randomization and must be acquired by multiphasic CT or contrast magnetic resonance imaging (MRI)
-
Date of last documented disease progression must be within 12 months from date of randomization
-
Prior everolimus and/or sunitinib therapy is allowed, so long as it was discontinued >= 4 weeks prior to randomization
-
Concurrent somatostatin analogues are allowed provided that patients
- Have been on a stable dose for 8 weeks and
- Have documented disease progression on that dose
-
Chemoembolization is allowed if ≥ 4 weeks from study entry. There are 2 possible scenarios:
- If patient has hepatic disease only: they need to have progressed in the liver since chemoembolization and have measurable disease by RECIST 1.1 in order to be eligible.
- If patient has hepatic and extrahepatic disease: they will need to have progressed inside OR outside the liver and have measureable disease by RECIST 1.1 in order to be eligible.
-
Leukocytes >= 3,000/mm^3
-
Absolute neutrophil count >= 1,500/mm^3
-
Hemoglobin >= 9 g/dL
-
Platelets >= 100,000/mm^3
-
Total bilirubin <= institutional upper limit of normal (ULN) or <= 1.5 X institutional ULN (if the patient has liver metastases)
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) <= 3 X institutional ULN or (<= 5 X institutional ULN if the patient has liver metastases)
-
Serum creatinine <= 1.5 X institutional ULN
-
Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Patient must have life expectancy >= 12 weeks all females of childbearing potential must have a blood test or urine study within =< 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study; should a woman become pregnant while participating in this study, she should inform her treating physician immediately; if a man impregnates a woman while participating in this study, he should inform his treating physician immediately
-
Patient must be able to swallow pills
-
Patient must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for their treatment and the protocol
Exclusion Criteria:
-
Small cell carcinoma
-
Prior temozolomide, dacarbazine (DTIC), or capecitabine, or 5-FU (fluorouracil) therapy
-
Receiving any other investigational agents while on study treatment
-
Receiving Coumadin while on treatment; other anticoagulants are allowed
-
Patients with either clinically apparent central nervous system metastases or carcinomatous meningitis are ineligible
-
Active or uncontrolled infection or serious medical or psychiatric illness
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or capecitabine
-
Absorption issues that would limit the ability to absorb study agents
-
Patients with a history of the following within 12 months of study entry:
- Arterial thromboembolic events
- Unstable angina
- Myocardial Infarction
-
Symptomatic peripheral vascular disease
-
Patients with previous or concurrent malignancy; exceptions are made for patients who meet any of the following conditions:
- Non-melanoma skin cancer, in situ cervical cancer, or breast cancer in situ OR
- Prior malignancy completely excised or removed and patient has been continuously disease free for > 5 years OR
- Prior malignancy cured by non-surgical modalities and patient has been continuously disease free for > 5 years
-
Pregnant or breast-feeding
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm A (temozolomide)
Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. |
Given PO
Andre navn:
|
|
Eksperimentell: Arm B (temozolomide and capecitabine)
Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. |
Given PO
Andre navn:
Given PO
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival
Tidsramme: Assessed every 3 months for 3 years and then every 6 months for years 3-5
|
Progression-free survival (PFS) is defined as the time from randomization to progression or death without evidence of progression. Progression was evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan-Meier method was used to estimate PFS. |
Assessed every 3 months for 3 years and then every 6 months for years 3-5
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Patients With Response
Tidsramme: Assessed every 3 months for 3 years and then every 6 months for years 3-5
|
Response was evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and defined as either complete response (CR) or partial response (PR). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. |
Assessed every 3 months for 3 years and then every 6 months for years 3-5
|
|
Overall Survival
Tidsramme: Assessed every 3 months for 3 years and then every 6 months for years 3-5
|
Overall survival is defined as time from randomization to death or date last known alive. |
Assessed every 3 months for 3 years and then every 6 months for years 3-5
|
|
Association Between Methyl Guanine Methyltransferase (MGMT) Status by Immunohistochemistry (IHC) and Response
Tidsramme: Assessed every 3 months for 3 years and then every 6 months for years 3-5
|
Response was evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and defined as either complete response (CR) or partial response (PR). CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. MGMT status was determined by IHC using paraffin-embedded sections of 4µm. A score (H-score) was generated based on the findings and scoring was performed by two pathologists. This H-score ranges from 0 (no staining in the tumor) to 300 (diffuse intense staining of the tumor). The highest score was used if there was disagreement. H-scores were grouped into 3 standard categories for MGMT status: Category 1 - <=50 Category 2 - 51-100 Category 3 - >100 |
Assessed every 3 months for 3 years and then every 6 months for years 3-5
|
|
Association Between Methyl Guanine Methyltransferase (MGMT) Status by Promoter Methylation and Response
Tidsramme: Assessed every 3 months for 3 years and then every 6 months for years 3-5
|
Response was evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and defined as either complete response (CR) or partial response (PR). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. MGMT status is determined by promoter methylation, a clinically validated methylation-specific polymerase chain reaction (PCR) analysis. A tumor sample is considered positive for MGMT promoter methylation if an 80bp band is detected in the methylated PCR reaction. It would be considered MGMT negative if an 80bp band is not detected in the methylated PCR reaction. |
Assessed every 3 months for 3 years and then every 6 months for years 3-5
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Pamela Kunz, ECOG-ACRIN Cancer Research Group
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Antatt)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i det endokrine systemet
- Neoplasmer etter nettsted
- Neoplasmer
- Neoplasmer etter histologisk type
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Neoplasmer i endokrine kjertel
- Pankreassykdommer
- Neoplasmer, kjertel og epitel
- Adenokarsinom
- Adenom
- Karsinom
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Nevroendokrine svulster
- Karsinom, nevroendokrine
- Neoplasmer i bukspyttkjertelen
- Adenom, øycelle
- Karsinom, øycelle
- Gastrinom
- Insulinom
- Glukagonom
- Somatostatinom
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Azoler
- Nukleinsyrer, nukleotider og nukleosider
- Dacarbazine
- Triazener
- Imidazoles
- Deoxycytidine
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Nukleosider
- Uracil
- Pyrimidinoner
- Deoxyribonucleosides
- Fluorouracil
- Temozolomid
- Capecitabin
Andre studie-ID-numre
- E2211
- U10CA180820 (U.S. NIH-stipend/kontrakt)
- U10CA021115 (U.S. NIH-stipend/kontrakt)
- E2211 (Annen identifikator: ECOG-ACRIN Cancer Research Group)
- NCI-2012-02007 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .